Tesamorelin is a stabilized 44-residue GHRH analog with an N-terminal trans-3-hexenoyl modification that resists DPP-4 degradation, studied for its stimulation of endogenous growth hormone release. Supplied as a ≥98% HPLC-verified lyophilized powder for laboratory research use only.
€ 59.99 – € 99.99Price range: € 59.99 through € 99.99
Third-Party Tested by Janoshik Analytical
Compound Information
Technical specifications
Lyophilized powder; keep sealed, dry, and protected from light
Store at a stable temperature; minimize warming/cooling cycles
Aliquot after reconstitution; avoid repeated freeze–thaw cycles
Lyophilized Powder
-20°C preferred; 2–8°C for short-term handling
Reconstituted
2–8°C
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), consisting of the full 44-residue human GHRH sequence with a trans-3-hexenoyl group attached at the N-terminus. This modification substantially slows degradation by dipeptidyl peptidase-4 (DPP-4), giving the peptide a longer functional half-life than native GHRH. It acts on pituitary GHRH receptors to stimulate endogenous growth hormone release, making it a reference compound for studying the GHRH–GH–IGF-1 axis, pulsatile secretion dynamics, and visceral adipose signaling. Supplied as a high-purity lyophilized powder for reproducible in-vitro and approved in-vivo work. This product is for laboratory research and development purposes only and must be handled by qualified professionals. Not for human, therapeutic, or diagnostic use.
Endogenous GH Release
Acts on pituitary GHRH receptors to stimulate the body’s own growth hormone output rather than supplying exogenous GH.
DPP-4 Resistance
The N-terminal trans-3-hexenoyl modification slows enzymatic cleavage, extending functional half-life relative to native GHRH.
GH–IGF-1 Axis Studies
A standard reference compound for investigating downstream IGF-1 signaling and hepatic response to GH stimulation.
Visceral Adipose Research
Widely referenced in preclinical models examining lipolytic signaling and visceral fat distribution.
Pulsatile Secretion Dynamics
Because it works upstream at the pituitary, it preserves the natural pulsatile pattern of GH release in study models.
≥98% HPLC Purity
Every batch is HPLC-verified and supplied lyophilized, ensuring reproducible results across long study timelines.
Tesamorelin is a synthetic 44-residue analog of growth hormone-releasing hormone (GHRH), modified at the N-terminus with a trans-3-hexenoyl group to resist enzymatic degradation.
The N-terminal modification slows cleavage by DPP-4, giving Tesamorelin a longer functional half-life than unmodified GHRH while retaining receptor activity.
Because it acts upstream at the pituitary rather than supplying exogenous hormone, it allows researchers to study endogenous GH release, pulsatile secretion patterns, and downstream IGF-1 signaling.
No. This product has not been evaluated by the FDA and is strictly intended for research and development purposes by qualified professionals only.
